

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- 1.-10. (Cancelled).
11. (Previously presented) An isolated polypeptide comprising:
 - (a) a polypeptide comprising any one of the amino acid sequences set forth in SEQ ID NOs: 1 and 3 to 12; or
 - (b) a polypeptide comprising a peptide region cyclized by a disulfide bond formed between cysteine residues on both ends of the polypeptide of (a).
12. (Previously presented) The polypeptide of claim 11, wherein the length of the polypeptide is 9 amino acids or less.
- 13.-14. (Cancelled).
15. (Previously presented) A pharmaceutical agent for conferring brain-localizing activity to an arbitrary molecule, wherein the agent comprises the polypeptide of claim 11.
16. (Original) The pharmaceutical agent of claim 15, wherein the arbitrary molecule is an arbitrary polypeptide.
17. (Previously presented) A molecule having brain-localizing activity, wherein the molecule comprises the polypeptide of claim 11.
18. (Original) The molecule of claim 17, wherein the molecule is a phage particle or a coat protein of a phage particle.
19. (Previously presented) The molecule of claim 17, wherein the molecule is a fusion protein formed with the polypeptide of claim 11.
20. (Previously presented) A carrier for delivery to the brain, wherein the carrier comprises the polypeptide of claim 11.

21. (Previously presented) A carrier for delivery to the brain, wherein the carrier comprises a structure in which the polypeptide of claim 11 is bound to a micelle, liposome, or microcapsule.

22. (Currently amended) A therapeutic agent for brain disease, wherein the agent comprises a structure in which a drug is supported by the carrier of claim 20 ~~[[or 21]]~~.

23. (Previously presented) A method for producing a molecule having brain-localizing activity, wherein the method comprises binding to an arbitrary molecule a polypeptide comprising any one of the amino acid sequences set forth in SEQ ID NOs: 1 and 3 to 12.

24. (Cancelled).

25. (Previously presented) A method for translocating an arbitrary molecule into the brain of an animal, wherein the method comprises the steps of:

(a) producing a molecule having brain-localizing activity, wherein the molecule comprises a structure in which an arbitrary molecule is bound to a polypeptide comprising any one of the amino acid sequences set forth in SEQ ID NOs: 1 and 3 to 12; and

(b) administering the molecule into the body of the animal.

26. (Currently amended) A method of screening for a molecule having binding activity to a polypeptide comprising any one of the amino acid sequences set forth in SEQ ID NOs: 1 and ~~[[3-12]]~~ 3 to 12, wherein the method comprises the steps of:

(a) contacting with a test molecule a polypeptide comprising any one of the amino acid sequences set forth in SEQ ID NOs: 1 and ~~[[3-12]]~~ 3 to 12;

(b) detecting binding activity between the polypeptide and the test molecule; and

(c) selecting a molecule that binds to the polypeptide.

27-30. (Cancelled)

31. (New) A therapeutic agent for brain disease, wherein the agent comprises a structure in which a drug is supported by the carrier of claim 21.